BusinessworldBusinessworld

Torrent Pharma Q2 Profit Drops 10%; Revenue Jumps 51%

阅读2分钟

Torrent’s base business grew 18 per cent, with India operations emerging as a key contributor to quarterly performance

Torrent Pharmaceuticals’ net profit declined 10 per cent year-on-year to Rs 534 crore in the second quarter of FY27, even as revenue surged 50.8 per cent following the consolidation of JB Chemicals & Pharmaceuticals.

Revenue from operations rose to Rs 4,979 crore from Rs 3,302 crore a year earlier, while operating EBITDA before exceptional items increased 53.8 per cent to Rs 1,666 crore. The operating EBITDA margin also improved to 33.5 per cent from 32.8 per cent.

The merger with JB Chemicals, which became effective on July 8, added significantly to Torrent’s revenue base. However, the company said the integration process created temporary pressure on business operations during the quarter.

“Following the merger, effective July 8, 2026, integration of the India business, global business network optimisation, and alignment of manufacturing and quality management systems, resulted in a transient impact on revenues during Q2 FY27,” Torrent Pharmaceuticals said in its earnings release.

Base Business Remains Strong

Excluding the newly integrated operations, Torrent’s base business revenue increased 18 per cent to Rs 3,893 crore during the quarter. The India business was a major growth driver, with revenue rising 20 per cent to Rs 2,181 crore.

The company’s India growth was ahead of the broader pharmaceutical market, which grew 12 per cent during the quarter, according to PharmaTrac data. Torrent said its branded markets continued to support the performance of the base business.

The JB Chemicals business contributed Rs 1,086 crore to quarterly revenue. Its India prescription business, excluding trade generics and contrast media, grew 7 per cent to Rs 597 crore.

Torrent’s international operations delivered mixed results during the quarter. Brazil revenue rose 38 per cent to Rs 440 crore, while revenue from the US increased 24 per cent to Rs 417 crore. Germany remained a weak spot, with revenue declining 7 per cent to Rs 283 crore. The company attributed the decline to supply disruptions at a third-party supplier and the loss of certain high-volume tenders.

The international business of JB Chemicals, covering the US, emerging markets and contract development and manufacturing operations, recorded revenue of Rs 406 crore, down 7 per cent year-on-year.

R&D Spending Increases

Torrent reported a gross margin of 75.4 per cent during the quarter, while research and development expenditure increased 35 per cent year-on-year to Rs 211 crore. R&D spending accounted for 4.2 per cent of quarterly revenue as the company continued to invest in its product pipeline alongside the integration of JB Chemicals.

For the first half of FY27, Torrent’s revenue increased 52.8 per cent to Rs 9,900 crore, while net profit declined 3.4 per cent to Rs 1,100 crore. Operating EBITDA rose 57.4 per cent to Rs 3,330 crore, with the margin at 33.6 per cent.

Shares of Torrent Pharmaceuticals ended 2.78 per cent lower at Rs 4,482 on the BSE.

阅读全文
在TradingView,您可以无限访问来自Businessworld和所有其他新闻来源的文章。